Meredith Kilgore, PhD, Paul Muntner, PhD, J

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

Modulation of High-Density Lipoproteins in a Population in Istanbul, Turkey, With Low Levels of High-Density Lipoproteins Robert W. Mahley, MD, PhD,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

“Sick Fat,” Metabolic Disease, and Atherosclerosis

“Sick Fat,” Metabolic Disease, and Atherosclerosis

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Association of Physical Activity and Renal Function in Subjects With and Without Metabolic Syndrome: A Review of the Third National Health and Nutrition.

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred Rossella Spina,

Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf

Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol,

Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Xing Wu, MD, PhD, Zhexin Yu, MD, MS, Wen Su, MD, PhD, Daniel A

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication.

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

III. Treating dyslipidemias

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

Presentation transcript:

Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults Meredith Kilgore, PhD, Paul Muntner, PhD, J. Michael Woolley, PhD, Pradeep Sharma, MS, Vera Bittner, MD, Robert S. Rosenson, MD Journal of Clinical Lipidology Volume 8, Issue 1, Pages 86-93 (January 2014) DOI: 10.1016/j.jacl.2013.11.001 Copyright © 2014 National Lipid Association Terms and Conditions

Figure 1 Exclusion criteria for National Health and Nutrition Examination Surveys (NHANES) 2005–2010 analyses. ATP III, Third Adult Treatment Panel; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride. Journal of Clinical Lipidology 2014 8, 86-93DOI: (10.1016/j.jacl.2013.11.001) Copyright © 2014 National Lipid Association Terms and Conditions

Figure 2 Differences in non–HDL-C and LDL-C, overall (top) and for persons with high non–HDL-C and normal LDL-C (middle) and for persons with high LDL-C and normal non–HDL-C (bottom). LDL-C, low-density lipoprotein cholesterol; non–HDL-C, non–high-density lipoprotein cholesterol. Journal of Clinical Lipidology 2014 8, 86-93DOI: (10.1016/j.jacl.2013.11.001) Copyright © 2014 National Lipid Association Terms and Conditions

Figure 3 Prevalence of high non–HDL-C and high LDL-C among US adults. LDL-C, low-density lipoprotein cholesterol; non–HDL-C, non-high-density lipoprotein cholesterol. Journal of Clinical Lipidology 2014 8, 86-93DOI: (10.1016/j.jacl.2013.11.001) Copyright © 2014 National Lipid Association Terms and Conditions